Pyrimidine and nucleoside γ-esters of L-Glu-Sar: Synthesis, stability and interaction with hPEPT1

European Journal of Pharmaceutical Sciences

Volumn 25, Issue 1, 2005, Pages 145-154

  Eriksson, André H ^a   Elm, Peter L ^a   Begtrup, Mikael ^a   Brodin, Birger ^a   Nielsen, Robert ^b   Steffansen, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aqueous stability; Bioreversible derivatives; Caco 2; Dipeptide; hPEPT1; Intracellular pH

Indexed keywords

2',7' BIS(2 CARBOXYETHYL) 5 CARBOXYFLUORESCEIN; 2',7' BIS(2 CARBOXYETHYL) 6 CARBOXYFLUORESCEIN; BUFFER; CARBON 14; DIPEPTIDE DERIVATIVE; FLUORESCENT DYE; GLUTAMINYL(2 THYMIN 1 YLTETRAHYDROFURAN 3 YL ESTER)SARCOSINE; GLUTAMINYL(ACYCLOTHYMIDINE)SARCOSINE; GLUTAMINYL(ACYCLOVIR)SARCOSINE; GLUTAMINYL(THYMIN 1 YLMETHYL ESTER)SARCOSINE; GLYCYLSARCOSINE; LYSYL[ZINC(NITROGEN DIOXIDE)]PROLINE; PEPTIDE TRANSPORTER 1; SARCOSINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BINDING COMPETITION; CELL ASSAY; CELL GROWTH; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; ENZYME DEGRADATION; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME SUBSTRATE; EPIFLUORESCENCE MICROSCOPE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; INTESTINE; ISOTOPE LABELING; LIQUID CULTURE; NONHUMAN; PH; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SWINE; TISSUE HOMOGENATE;

EID: 18044386200     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.02.007     Document Type: Article

References (40)

1. S. Ahmad, S. Ozaki, T. Nagase, M. Iigo, R. Tokuzen, and A. Hoshi A facile method for synthesis of N-acyloxymethyl-5-fluorouracils, as a class of antitumor agents Chem. Pharm. Bull. 35 1987 4137 4143
2. L.M. Beauchamp, G.F. Orr, P. de Miranda, T.C. Burnette, and T.A. Krenitsky Amino acid ester prodrugs of acyclovir Antivir. Chem. Chemother. 3 1992 157 164
3. D. Brigden, P. Fiddian, A.E. Rosling, and T. Ravenscroft Acyclovir - a review of the preclinical and early clinical data of a new antiherpes drug Antiviral Res. 1 1981 203 212
4. T.C. Burnette, and P. de Miranda Metabolic disposition of the acyclovir prodrug valaciclovir in the rat Drug Metab. Dispos. 22 1994 60 64
5. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (KI) and the concentration of inhibitor, which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
6. D. Craig, V.R. Munasinghe, J.P. Tierney, A.J.P. White, D.J. Williams, and C. Williamson Template-directed intramolecular C-glycosidation. Cation-mediated synthesis of ketooxetanes from thioglycosides Tetrahedron 55 1999 15025 15044
7. R.J. Crooks, and A. Murray Valaciclovir - a review of a promising new antiherpes agent Antivir. Chem. Chemother. 5 Suppl. 1 1994 31 37
8. A.L. Daugherty, and R.J. Mrsny Transcellular uptake mechanisms of the intestinal epithelial barrier Part one Pharm. Sci. Technol. Today 2 1999 144 151
9. G.M. Friedrichsen, C.U. Nielsen, B. Steffansen, and M. Begtrup Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides Eur. J. Pharm. Sci. 14 2001 13 19
10. M.E. Ganapathy, W. Huang, H. Wang, V. Ganapathy, and F.H. Leibach Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2 Biochem. Biophys. Res. Commun. 246 1998 470 475
11. L. Gu, and R.G. Strickley Diketopiperazine formation, hydrolysis and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085 Pharm. Res. 4 1987 392 397
12. L. Gu, and R.G. Strickley Preformulation stability studies of the new dipeptide angiotensin-converting enzyme inhibitor RS-10029 Pharm. Res. 5 1988 765 771
13. H. Han, R.L. de Vrueh, J.K. Rhie, K.M. Covitz, P.L. Smith, C.P. Lee, D.M. Oh, W. Sadee, and G.L. Amidon 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter Pharm. Res. 15 8 1998 1154 1159
14. C. Heidelberger, N.K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, R.J. Schnitzer, E. Pleven, and J. Scheiner Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 4561 1957 663 666
15. M. Johansen, and H. Bundgaard Pro-drugs as drug delivery systems. Part 16: novel water soluble pro-drug types for chlorzoxazone by esterification of the N-hydroxymethyl derivative Arch. Pharm. Chem. Sci. Ed. 9 1981 43 54
16. I. Knütter, B. Hartrodt, S. Theis, M. Foltz, M. Rastetter, H. Daniel, K. Neubert, and M. Brandsch Analysis of the transport properties of side chain modified dipeptides at the mammalian peptide transporter PEPT1 Eur. J. Pharm. Sci. 21 2004 61 67
17. I. Knütter, S. Theis, B. Hartrodt, I. Born, M. Brandsch, H. Daniel, and K. Neubert A novel inhibitor of the mammalian peptide transporter PEPT1 Biochemistry 40 2001 4454 4458
18. E. Krondahl, A. Orzechowski, G. Ekstrom, and H. Lennernas Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats Pharm. Res. 14 1997 1780 1785
19. C. Larsen, and H. Bundgaard Kinetics and mechanism of degradation of mecillinam in aqueous solution Arch. Pharm. Chem. Sci. Ed. 5 1977 66 86
20. E.I. Lepist, T. Kusk, D.H. Larsen, D. Andersen, S. Frokjaer, M.E. Taub, P. Veski, H. Lennernas, G. Friedrichsen, and B. Steffansen Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter Eur. J. Pharm. Sci. 11 2000 43 50
21. A.J. Lin, R.S. Benjamin, P.N. Rao, and T.L. Loo Synthesis and biological activities of ftorafur metabolites: 3′- and 4′-hydroxyftorafur J. Med. Chem. 22 1979 1096 1100
22. D.B. Longley, D.P. Harkin, and P.G. Johnston 5-fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 2003 330 338
23. T. Matthews, and R. Boehme Antiviral activity and mechanism of action of ganciclovir Rev. Infect. Dis. 10 1988 S490 S494
24. H. Mitsuya, and S. Broder Strategies for antiviral therapy in AIDS Nature 325 1987 773 778
25. G.D. Morse, M.J. Shelton, and A.M. O'Donnell Comparative pharmacokinetics of antiviral nucleoside analogues Clin. Pharmacokinet. 24 1993 101 123
26. C.U. Nielsen, J. Amstrup, B. Steffansen, S. Frokjaer, and B. Brodin Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G191 G199
27. C.U. Nielsen, R. Andersen, B. Brodin, S. Frokjaer, and B. Steffansen Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media J. Control. Release 73 2001 21 30
28. C.U. Nielsen, R. Andersen, B. Brodin, S. Frokjaer, M.E. Taub, and B. Steffansen Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line J. Control. Release 76 2001 129 138
29. B. Steffansen, E.I. Lepist, M.E. Taub, B.D. Larsen, S. Frokjaer, and H. Lennernas Stability, metabolism and transport of d-Asp(OBzl)-Ala - a model prodrug with affinity for the oligopeptide transporter Eur. J. Pharm. Sci. 8 1999 67 73
30. W.C. Still, M. Kahn, and A.K. Mitra Rapid chromatographic technique for preparative separations with moderate resolution J. Org. Chem. 43 1978 2923 2925
31. M. Sugawara, W. Huang, Y.J. Fei, F.H. Leibach, V. Ganapathy, and M.E. Ganapathy Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2 J. Pharm. Sci. 89 2000 781 789
32. F. Sweet, and R.K. Brown 2-Alkoxy-3-hydroxytetrahydropyrans and 2-alkoxy-3-hydroxytetrahydrofurans. Part I: preparation structure and some derivatives Can. J. Chem. 44 1966 1571
33. M.E. Taub, B.A. Moss, B. Steffansen, and S. Frokjaer Influence of oligopeptide transporter binding affinity upon uptake and transport of d-Asp(OBzl)-Ala and Asp(OBzl)-Sar in filter grown Caco-2 monolayers Int. J. Pharm. 156 1997 219 228
34. M.E. Taub, B.A. Moss, B. Steffansen, and S. Frokjaer Oligopeptide transporter-mediated uptake and transport of d-Asp(OBzl)-Ala, d-Glu(OBzl)-Ala, and d-Ser(Bzl)-Ala in filter-grown Caco-2 monolayers Int. J. Pharm. 174 1998 223 232
35. A.E. Thomsen, M.S. Christensen, M.A. Bagger, and B. Steffansen Acyclovir prodrug for the intestinal di-/tri-peptide transporter PEPT1: comparison of transport in Caco-2 cells and in vivo bioavailability in rats Eur. J. Pharm. Sci. 23 2004 319 325
36. A.E. Thomsen, G.M. Friedrichsen, A.H. Sorensen, R. Andersen, C.U. Nielsen, B. Brodin, M. Begtrup, S. Frokjaer, and B. Steffansen Prodrugs of purine and pyrimidine analogues for the intestinal di-/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism J. Control. Release 86 2003 279 292
37. D.T. Thwaites, B.H. Hirst, and N.L. Simmons Direct assessment of dipeptide/H+ symport in intact human intestinal (Caco-2) epithelium: a novel method utilising continuous intracellular pH measurement Biochem. Biophys. Res. Commun. 194 1993 432 438
38. M. Ubasawa, H. Takashima, and K. Sekiya A convenient one-pot synthesis of acyclonucleosides Chem. Pharm. Bull. 43 1995 142 143
39. J. Våbenø, T. Lejon, C.U. Nielsen, B. Steffansen, W.Q. Chen, O.Y. Hui, R.T. Borchardt, and K. Luthman Phe-Gly dipeptidomimetics designed for the di-/tri-peptide transporters PEPT1 and PEPT2: synthesis and biological investigations J. Med. Chem. 47 2004 1060 1069
40. J. Våbenø, C.U. Nielsen, T. Ingebrigtsen, T. Lejon, B. Steffansen, and K. Luthman Dipeptidic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tri-peptide transporter hPEPT1: Design, synthesis, stability and biological investigations J. Med. Chem. 47 2004 4755 4765